Oramed Pharmaceuticals Inc.ORMPNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | -166.98% | -304.86% | +18.03% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -176.40% | -597.53% | +44.25% | +0.00% |
| EPS Growth | +0.00% | -178.79% | -605.32% | +45.45% | +0.00% |
| EPS Diluted Growth | +0.00% | -178.79% | -613.51% | +40.91% | +0.00% |
| Weighted Average Shares Growth | +1.11% | -1.14% | +0.96% | +1.91% | +2.10% |
| Weighted Average Shares Diluted Growth | +1.11% | -1.45% | -0.81% | +2.45% | +4.59% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -272.33% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -272.52% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -28.50% | -29.60% | -27.55% | -12.23% | +33.57% |
| Book Value per Share Growth | +3.74% | -9.69% | -16.30% | -14.37% | +27.27% |
| Debt Growth | -99.44% | -99.28% | -99.08% | +87.65% | +100.47% |
| R&D Expense Growth | +134.27% | -17.27% | +87.11% | -28.29% | -48.57% |
| SG&A Expenses Growth | -56.25% | +1.09% | +29.39% | -14.06% | +50.41% |